logo-loader
viewNetscientific PLC

NetScientific portfolio companies Vortex Biosciences and Wanda to be wound up

NetScientific also announced that PDS and Edge Therapeutics have completed their all-share merger

NetScientific
NetScientific invests in development-stage medical and healthcare businesses

NetScientific PLC (LON:NSCI) said on Monday that its portfolio companies Vortex Biosciences and Wanda Inc are set to be wound up.

The firm, which invests in development-stage medical and healthcare businesses, had received an indicative proposal from a third party for the sale of its shareholdings in Vortex and Wanda.

READ: NetScientific expects shareholders to reject plan to delist from AIM and become private company

But after considering the indicative terms of the potential disposal and the expected timeline to complete a deal, NetScientific concluded that “the level of consideration offered is not sufficient to justify the company continuing to provide the necessary financial support to Wanda and Vortex” while it carries out due diligence and negotiations.

The group said such a move would affect the company’s ability to allocate sufficient cash resources to its other portfolio companies Glycotest Inc., ProAxsis Ltd and PDS BioTechnology. NetScientific believes these portfolio companies have the “most realistic prospects” of delivering shareholder returns.

“The board has therefore concluded that it was not in the best interests of the company to proceed with the potential disposal,” it said.

“Subsequently, the directors of Vortex and Wanda respectively resolved to effect the orderly wind up of those companies.”

In a separate announcement, NetScientific announced that PDS and Edge Therapeutics Inc. (NASDAQ:EDGE) have completed their all-share merger.

READ: NetScientific lifted as portfolio company PDS Biotechnology announces merger with Edge Therapeutics

The combined company will trade under the PDS name and will start trading on Nasdaq today under the ticker PDSB.

NetScientific's chief executive Francois Martelet said: "We are delighted that the merger has completed, and with the liquidity attributable to NetScientific's holding in PDS Biotechnology Corporation following the listing on Nasdaq."

Quick facts: Netscientific PLC

Price: 6 GBX

AIM:NSCI
Market: AIM
Market Cap: £4.71 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Netscientific PLC named herein, including the promotion by the Company of Netscientific PLC in any Content on the Site, the Company receives...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Investor Update: ANGLE reports positive data from Parsortix FDA clinical study

Top stories from the Proactive Investors UK newsroom: ANGLE PLC (LON:AGL) has received positive results from its Parsortix FDA clinical study for metastatic breast cancer. The 400-subject clinical study will support an application for Class II regulatory clearance for Parsortix in the...

on 31/5/19

2 min read